Definium Therapeutics, Inc.
DFTX
Rang in aandelen
#3538
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Aandeelprijs
$35.52
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$4.77B
Verandering (1 dag)
1.24%
Verandering (1 jaar)
185.79%
Land
US
Handel Definium Therapeutics, Inc. (DFTX)
Categorie
Healthcare
Koersgeschiedenis voor Definium Therapeutics, Inc. (DFTX)
Hoogste slotkoers: $35.12 op 2026-10-01
Laagste slotkoers: $4.81 op 2016-11-01
Laagste slotkoers: $4.81 op 2016-11-01
Koersgeschiedenis van Definium Therapeutics, Inc. van 2016 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 98.99% |
| 2025 | 74.98% |
| 2024 | 107.98% |
| 2023 | 34.70% |
| 2022 | -89.90% |
| 2021 | -40.72% |
| 2020 | 7,946.66% |
| 2019 | -31.09% |
| 2018 | -81.58% |
| 2017 | -37.50% |
| 2016 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
